Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States

Clinical Therapeutics

Volumn 34, Issue 9, 2012, Pages 1966-1976

  Pan, Feng ^a   Goh, Jo Wern ^a   Cutter, Gary ^b   Su, Wayne ^a   Pleimes, Dirk ^c   Wang, Cheng ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

Cost effectiveness; Economic; Interferon beta 1b; Multiple sclerosis; Societal perspective

Indexed keywords

INTERFERON BETA SERINE; PLACEBO;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE COST; HUMAN; LONG TERM CARE; MORTALITY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES;

ADJUVANTS, IMMUNOLOGIC; AGED; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; MULTIPLE SCLEROSIS; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 84866146234     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.07.010     Document Type: Article

References (36)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993, 43:655-661.
2. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995, 45:1277-1285.
3. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352:1498-1504.
4. Durelli L., Verdun E., Barbero P., et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002, 359:1453-1460.
5. Jacobs L.D., Cookfair D.L., Rudick R.A., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39:285-294.
6. Johnson K.P., Brooks B.R., Cohen J.A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268-1276.
7. Panitch H., Goodin D.S., Francis G., et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002, 59:1496-1506.
8. Bronnum-Hansen H., Koch-Henriksen N., Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004, 127:844-850.
9. Grytten Torkildsen N., Lie S.A., Aarseth J.H., et al. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 2008, 14:1191-1198.
10. Hirst C., Swingler R., Compston D.A., et al. Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry 2008, 79:1016-1021.
11. Leray E., Morrissey S.P., Yaouanq J., et al. Long-term survival of patients with multiple sclerosis in West France. Mult Scler 2007, 13:865-874.
12. Sumelahti M.L., Hakama M., Elovaara I., Pukkala E. Causes of death among patients with multiple sclerosis. Mult Scler 2010, 16:1437-1442.
13. Wallin M.T., Page W.F., Kurtzke J.F. Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis. Brain 2000, 123(Pt 8):1677-1687.
14. Goodin D.S., Reder A.T., Ebers G.C., et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012, 78:1315-1322. Accessed June 5, 2012. http://www.neurology.org/content/early/2012/04/11/WNL.0b013e3182535cf6.abstract.
15. Bell C., Graham J., Earnshaw S., et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007, 13:245-261.
16. Noyes K., Bajorska A., Chappel A., et al. Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study. Neurology 2011, 77:355-363.
17. Prosser L.A., Kuntz K.M., Bar-Or A., Weinstein M.C. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health 2004, 7:554-568.
18. Tappenden P., McCabe C., Chilcott J., et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health 2009, 12:657-665.
19. Kobelt G., Berg J., Atherley D., et al. Costs and quality of life in multiple sclerosis: a cross-sectional ttudy in the USA. SSE/EFI Working Paper Series in Economics and Finance No 594 2004, The Economic Research Institute, Stockholm School of Economics, Stockholm, Sweden, Accessed September 12, 2011. http://swopec.hhs.se/hastef/papers/hastef0594.pdf.
20. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112(Pt 1):133-146.
21. Gold M.R. Cost-effectiveness in Health and Medicine 1996, Oxford University Press, New York, NY.
22. Ebers G.C., Traboulsee A., Li D., et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010, 81:907-912.
23. Bermel R.A., Weinstock-Guttman B., Bourdette D., et al. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler 2010, 16:588-596.
24. Goodkin D.E., Hertsgaard D., Rudick R.A. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989, 46:1107-1112.
25. Richards R.G., Sampson F.C., Beard S.M., Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002, 6:1-73.
26. Chilcott J., McCabe C., Tappenden P., et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. BMJ 2003, 326:522. discussion 522.
27. Tappenden P., Chilcott J.B., Eggington S., et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004, 8:iii. 1-78.
28. Thomson P.D.R. Red Book 2011, Wholesale Acquisition Cost 2011, Thomson Reuters, Montvale, NJ.
29. Market research file 2010, Bayer, (unpublished data).
30. O'Brien J.A., Ward A.J., Patrick A.R., Caro J. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003, 3:17.
31. Naci H., Fleurence R., Birt J., Duhig A. Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 2010, 28:363-379.
32. 2009 Annual mean wage from all occupations US Bureau of Labor Statistics, Accessed September 12, 2011. http://www.bls.gov/oes/current/oes_nat.htm#(2).
33. Marrie R., Horwitz R., Cutter G., et al. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008, 14:1091-1098.
34. Garber A.M., Phelps C.E. Economic foundations of cost-effectiveness analysis. J Health Econ 1997, 16:1-31.
35. Minden S.L., Frankel D., Hadden L., et al. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006, 12:24-38.
36. Tappenden P., Chilcott J.B., O'Hagan A., et al. Cost-effectiveness of Beta Interferon and Glatiramer Acetate in the Management of Multiple Sclerosis. Report to the National Institute for Clinical Excellence 2001, National Institute for Clinical Excellence (NICE), London, UK.